Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Pectoralis Minor Release Versus Non-release i RSA

10 november 2026 uppdaterad av: Eric Wagner, Emory University

Ett randomiserat kontrollförsök för att utvärdera frisättning kontra icke-frisättning av Pectoralis Minor med omvänd axelprotesplastik

The goal of this clinical trial is to assess if concomitant open pectoralis minor release would improve pain and outcomes after Reverse Shoulder Arthroplasty (RSA). The main questions it aims to answer are:

  • whether releasing the pectoralis minor prophylactically could have better pain relief
  • whether releasing the pectoralis minor prophylactically could have increased Range of motion (ROM) outcomes
  • whether releasing the pectoralis minor prophylactically could have higher final Patient Reported Outcome Measurements (PROMs) Participants will be randomized to either undergo RSA with pectoralis minor release or RSA without pectoralis minor release.

Studieöversikt

Detaljerad beskrivning

Shoulder arthroplasty has been increasing at exponential rates, particularly due to the rise of reverse shoulder arthroplasty (RSA). Postoperative complications after RSA include infection, instability, hardware component loosening, acromial and scapular spine fractures, neurologic injury, and scapular notching which can all cause pain. However, despite excluding these causes, some patients can have persistent anterior shoulder pain with poor motion.

RSA prostheses work by translating the center of rotation (COR) inferiorly and medially, which increases tension on the deltoid, which is thought to increase the deltoid's mechanical moment arm and thus its ability to abduct and flex the humerus. However, excessive lengthening may be a cause of acromial and scapular spine fractures or neurologic injury. In addition, other structures are tensioned, including the conjoint tendon (short head of the biceps brachii and coracobrachialis) and pec minor (PM). It is unclear if lengthening these muscle-tendon units has functional consequences or whether it can create an intrinsic pathology. It is therefore feasible that muscle lengthening could create tendinitis, which could lead to persistent anterior shoulder pain after RSA. In addition, excessive tension or over-activity in the PM is also known to be a cause of altered scapula biomechanics.

Good scapula biomechanics after RSA are critical to preserving an impingement-free range of motion, which is important in maximizing postoperative outcomes, implant longevity, and preventing component loosening and instability. However, it is known from the non-arthroplasty population that during repetitive movements with scapular protraction, a hyperactive or spasming PM shortens and develops contracture, leading to protracted resting scapular position and altered scapular contribution to shoulder range of motion.1 This causes altered scapular kinematics, or dyskinesia, and alters scapular accommodation to shoulder motion, a well-known feature in various shoulder pathologies. This can be a major problem after RSA when scapula accommodation is critical to ROM and function.

Due to the expendability of the pectoralis minor, its release would cause minimal functional detriment in non-pathological cases, but in cases of overactivity, release could markedly improve scapula biomechanics. This can be performed open or arthroscopically, but the concomitant open release would be straight-forward at the time of the index surgery through the same incision

Studietyp

Interventionell

Inskrivning (Faktisk)

90

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Georgia
      • Atlanta, Georgia, Förenta staterna, 30322
        • Emory Clinic
      • Atlanta, Georgia, Förenta staterna, 30329
        • Emory Healthcare Orthopaedics and Spine Center

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • All patients undergoing surgery for reverse total shoulder arthroplasty
  • Patients willing and able to provide informed consent

Exclusion Criteria:

  • Revision arthroplasty
  • Reverse shoulder arthroplasty for proximal humerus fractures
  • Adults unable to consent
  • Individuals who are not yet adults (infants, children, teenagers)
  • Pregnant women
  • Prisoners

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Enda

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: RSA med pectoralis minor frisättning

The pectoralis minor is a muscle on the anterior chest wall attaching to the coracoid process. In the group undergoing pectoralis minor release, through the same deltopectoral incision that will not be extended or different as compared to the RSA only group, the pec minor will be exposed on the medial aspect of the coracoid at the upper part of the incision. It will be cut from its insertion on the coracoid while being careful to protect any neurovascular structures.

RSA is the current Standard of Care (SOC)

Aktiv komparator: RSA utan pectoralis minor frisättning

RSA is the current Standard of Care (SOC)

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Visual analog Scale (VAS) pain scores
Tidsram: Baseline, 6 months

The Visual Analogue Scale (VAS) measures pain intensity. The VAS consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be'). Study participants will be asked to rate their current level of pain by placing a mark on the line

Baseline, 6 months

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Visual analog Scale (VAS) pain scores
Tidsram: Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 1 year (each follow-up visit)

The Visual Analogue Scale (VAS) measures pain intensity. The VAS consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be'). Study participants will be asked to rate their current level of pain by placing a mark on the line

Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 1 year (each follow-up visit)
American Shoulder and Elbow Score (ASES)
Tidsram: Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 1 year (each follow-up visit)

The ASES is a 100-point scale that consists of two dimensions: pain and activities of daily living. There is one pain scale worth 50 points and ten activities of daily living worth 50 points.

Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 1 year (each follow-up visit)
Subjective Shoulder Value (SSV)
Tidsram: Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 1 year (each follow-up visit)

Subjective Shoulder Value is study participant's subjective shoulder assessment expressed as a percentage of an entirely normal shoulder, which would score 100%

Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 1 year (each follow-up visit)
Change in Range of motion (ROM)
Tidsram: Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 1 year (each follow-up visit)

ROM is calculated in terms of angles. Lower number suggests restricted motion.

Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 1 year (each follow-up visit)
Change in Scapulohumeral Rhythm (SHR) on Digital Dynamic Radiography (DDR)
Tidsram: Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 1 year (each follow-up visit)

SHR is the ratio of humeral abduction over the change in scapula upward rotation during humeral abduction. This SHR will be captured on Digital Dynamic Radiography (DDR) and reported as a change in SHR before and after the interventions.

Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 1 year (each follow-up visit)
Number of complications
Tidsram: 1 year

Number of complications post intervention would be measured.

1 year
Number of reoperations
Tidsram: 1 year

Number of reoperations following intervention would be measured.

1 year

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Eric Wagner, MD, Emory University

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

7 augusti 2024

Primärt slutförande (Beräknad)

1 december 2027

Avslutad studie (Beräknad)

1 december 2027

Studieregistreringsdatum

Först inskickad

15 februari 2024

Först inskickad som uppfyllde QC-kriterierna

2 mars 2024

Första postat (Faktisk)

5 mars 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

13 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

10 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera